Growth through acquisitions The group has a track record of expanding through acquisitions (e.g., Laboratoires Grimberg in 2022), signaling potential interest in partnerships or joint ventures with contract development and manufacturing organizations (CDMO) to accelerate product portfolio expansion.

Domestic production strength All production sites are located in France with a sizable workforce, indicating a strong local manufacturing base that could be a selling point for French-focused supply chain services, regulatory support, and localized packaging or formulation capabilities.

Diverse health portfolio A diversified portfolio across pharmaceuticals, cosmetics, hygiene, and spa services, plus a leading baby product position in France, creates cross-sell opportunities for contract manufacturing, regulatory consulting, and private-label partnerships in multiple consumer health segments.

Digital and analytics readiness Usage of SAS, IBM i, WordPress, Zendesk, and Google Analytics indicates a technology-forward operations stance; opportunities exist to offer advanced data analytics, e-commerce optimization, CRM enhancements, and supply-chain visibility solutions.

Leadership and growth potential Recent leadership changes and a revenue tier reflecting mid-market scale, combined with a €200M+ revenue benchmark (2020), suggest openness to strategic partnerships, funding-backed capex, and scalable distribution deals to sustain growth across 86 exporting countries.